First Patient Dosed in Phase II Study of L-DOS47 in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer

AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ) ("Helix" or the "Company"), a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.

" This brings us closer to providing new treatment options to late stage cancer patients, " said Dr. Sven Rohmann, Chief Executive Officer of Helix. Up to forty-five (45) patients will be enrolled in the Phase II open-label, non-randomized study designed to make a preliminary assessment of efficacy of L-DOS47 in patients with non-squamous non-small cell lung cancer ("NSCLC").

About L-DOS47 L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About L-DOS47 clinical development L-DOS47 is currently being clinically evaluated in two clinical studies, in Poland and in the United States, as a treatment for certain patients with "NSCLC".

LDOS002 is an open-label Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study is being conducted at five Polish centers: the Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, the Military Medical Institute, the National Tuberculosis and Lung Diseases Research Institute, the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock and the Department of Oncology, Poznan University of Medical Science.

On September 8 th , 2015, the company presented results from the ongoing LDOS002 study at the 16th World Conference on Lung Cancer held in Denver, Colorado. Results from patients enrolled in the first twelve dosing cohorts included:

  • L-DOS47 was well tolerated at dose levels studied to-date;
  • Twenty-one (21) of the 40 patients enrolled (52%) had an overall response of 'stable disease' after completion of two cycles of L-DOS47;
  • Eleven (11) of the 21 patients had a response of 'stable disease' after completing four cycles of L-DOS47;
  • One (1) patient in the 9 th dosing cohort (1.84µg/kg) was dosed for 10 cycles (approximately 7 months) without disease progression.

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the United States at three centers: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/ carboplatin.

On March 3 rd , 2016, the company reported on the progress of study LDOS001. A patient in the first dosing cohort received four cycles of L-DOS47 in combination with pemetrexed/carboplatin and an additional four cycles of L-DOS47 alone before progression of their disease. The best response reported for this patient was a 37% decrease in the sum of the diameters of target lesions identified at baseline.

About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the total number of patients that will be enrolled in the Polish Phase I/II clinical study and the potential generation of valuable information by such further enrollment of patients, which may be identified by words including, without limitation, "will", "may", "anticipated", and other similar expressions, are intended to provide information about management's current plans and expectations regarding the conduct of the clinical study.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully, including that patient recruitment for the Polish Phase I/II clinical trial for L-DOS47 does not continue as scheduled or at all, that Helix's planned U.S. Phase I clinical trial for L-DOS47 proceeds in a manner and on the timelines anticipated by Helix, or at all and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results and that the information, if any, gained from higher dose levels in such study will not be of use in future studies; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.  These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Fax: (905) 841-2244 Email: ir@helixbiopharma.com Web: www.helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 141

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 113

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 103

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 176

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 88

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 91

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 154

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 87

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

LXP Industrial Trust's Strong First Quarter Performance Revealed

Updated Category News Views 197

LXP Industrial Trust Reports Strong Financial Results Today, LXP Industrial Trust (NYSE: LXP), a real estate investment trust specializing in Class A warehouse and distribution facilities, outlines its robust performance for the first quarter of 2025. Key financial figures and strategic developments reflect the company's growth trajectory in the dynamic real estate...

Continue Reading
AI in Diagnostics: A Bright Future with Rapid Growth Ahead

Updated Category News Views 314

AI in Diagnostics Market Overview In recent years, the integration of Artificial Intelligence (AI) into the diagnostics sector has shown remarkable potential. As healthcare progresses, the reliance on AI technology for early disease detection and diagnosis is becoming increasingly vital. The current healthcare landscape is witnessing an upsurge in the occurrence of...

Continue Reading
Fund Manager Scott Bessent Bets Big on Trump's Economic Policies

Updated Category News Views 312

Scott Bessent's Strategic Bet on Trump As a prominent figure in the investment community, Scott Bessent's journey has seen significant highs and lows. Currently, he finds himself in a pivotal moment, leveraging the political climate surrounding President-elect Donald Trump to make strategic moves that might reshape his career and the future of Key Square Capital...

Continue Reading
Mifflinburg Bancorp and Northumberland Bancorp Unite for Growth

Updated Category News Views 161

Mifflinburg Bancorp and Northumberland Bancorp Unite Mifflinburg Bancorp, Inc. (OTCPK: MIFF) and Northumberland Bancorp (OTCPK: NUBC) have officially revealed a strategic merger that is poised to transform the financial landscape. This merger, described as a union of equals, will create a new entity with significant resources aimed at improving capabilities and...

Continue Reading
ZTE's CDO Unveils Future of Intelligence at Key Shanghai Event

Updated Category News Views 215

ZTE's Vision for Intelligent Evolution at MWC25 ZTE Corporation (0763.HK / 000063.SZ), a prominent provider of information and communication technology solutions, made a significant impact at MWC25 in Shanghai. During this year’s event, Cui Li, Chief Development Officer of ZTE, captivated an audience during her keynote address titled "Digital and Intelligent Evolution:...

Continue Reading